Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more
here
.
About Us
About hVIVO
Leadership Team
Our Companies
Key Stats
History
Services
New
Challenge Trials
RSV
Influenza
COVID-19
HRV
Malaria
Asthma & COPD
hMPV
Phase II-III Trials
Vaccine Phase II-III Trials
Laboratory Services
Assay Development
Field Trial Bio-logistics
Cell Based Assays
Molecular Services
Compound Efficacy & VRM
Biomarker Analysis
Articles & Research
News & Media
Regulatory News
Media Coverage
Media Press Kit
Video Library
Events
Investors
New
Investors
Regulatory News & Email Alerts
Results Centre
Share Price Information
Events & Presentations
Environmental, Social & Governance
AIM Rule 26
Advisors
Documents
Corporate Governance
Volunteers
Careers
Contact Us
Contact Us
05 May 2021
Go Back
How Human Challenge Trials Can Accelerate Vaccine Development
Share this:
Other recent posts
Article
Pharma Focus Asia, Issue 52, 2023 – Human Challenge Trials: Establishing early risk-benefit in development of vaccines and therapies for infectious diseases
Featured on pages 54-56
View Link
Scientific Paper
Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study
Effectively implementing strategies to curb SARS-CoV-2 transmission requires understanding who is contagious and when. Although viral load on upper respiratory swabs has commonly been used to infer contagiousness, measuring viral...
View Link
If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.
Contact hVIVO
twitter
facebook
envelope
linkedin
angle-down
xing
paper-plane
pinterest-p
whatsapp
commenting
meetup
chevron-down